{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-108835","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.995229+00:00","generated_at":"2026-05-17T13:20:47.953216+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tivic Health Q2 revenue down 39% to $86k; net loss widens to $1.9M; plans to exit ClearUP, focus on biopharma","bullets":["Revenue $86k (-39% YoY); net loss $1.9M vs $1.3M in Q2 2024; cash $1.2M at June 30.","Raised $0.9M post-quarter; $7M committed via preferred equity; no debt on balance sheet.","Plans to exit ClearUP consumer healthtech by year-end; shifts resources to TLR5 agonist Entolimod.","Extended Entolimod license to include neutropenia; completed study visits for ncVNS device.","Named Lisa Wolf as permanent CFO; expanded biopharma team with regulatory and clinical staff."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-108835","json":"https://secwatch.observer/filing/0000950170-25-108835.json","markdown":"https://secwatch.observer/filing/0000950170-25-108835.md","text":"https://secwatch.observer/filing/0000950170-25-108835.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025108835/0000950170-25-108835-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025108835/tivc-20250814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:20:47.953216+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}